PSA Milestone That Best Predicts Survival in Metastatic Prostate Cancer Identified

Wider prostate cancer screening needed: doctors

Doctors are calling for wider prostate cancer screenings in Taiwan after former US president Joe Biden’s late-stage prostate cancer diagnosis drew attention to the disease, adding that only 3 to 5 percent of cases in the US were diagnosed at a metastatic stage, thanks to widespread screenings.The me

Optimal prostate-specific antigen cutoff linked to improved prostate cancer survival

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working.

PSA Milestone That Best Predicts Survival in Metastatic Prostate Cancer Identified

Patients with metastatic castration-sensitive prostate cancer (mCSPC) whose prostate-specific antigen (PSA) levels fall below 0.2 ng/mL within nine months of starting treatment live significantly longer than those who do not, according to a large study of nearly 5,000 U.S. veterans published in CANCER. The findings suggest that reaching this PSA threshold is a better indicator of treatment success than achieving a 90% drop in PSA levels—a benchm…

MRI-Derived PSA Density for Risk Stratification of PI-RADS 3 Peripheral Zone Lesions: Correlation with Radical Prostatectomy Pathology

Purpose Although prostate-specific antigen density (PSAD) has been extensively investigated as an adjunctive biomarker for risk stratification of PI-RADS 3 lesions, most previous studies have relied on biopsy findings as the pathological reference standard. We aimed to evaluate the di...

Spatial Transcriptomics: Decoding the Molecular Evolution of Prostate Cancer

Prostate cancer (PCa) is a highly prevalent malignancy, heavily characterized by complex cellular heterogeneity and highly variable clinical outcomes.

Which PSA cutoff best indicates successful prostate cancer treatment?

A new real-world study of nearly 5,000 men with metastatic hormone-sensitive prostate cancer suggests that one specific treatment milestone may provide a clearer signal of survival than the percentage by which prostate-specific antigen, or PSA, falls. Patients whose PSA concentration dropped below 0.2 nanograms per milliliter within nine months of beginning therapy were substantially less likely to die during follow-up than those whose levels re…